despit spinraza revenu miss patient number continu grow
report spinraza spinal muscular atrophi sale
vs consensu per factset patient number continu
climb spinraza sale reflect commerci patient growth us
commerci patient growth exu vs revenu miss
appear primarili relat mix patient load dose vs
mainten dose stage recal patient get monthli inject first
month dose everi month thereaft biogen
estim june patient global therapi
across post market set eap clinic trial accord
compani seen meaning impact launch
zolgensma date
emerg leader continu see risdiplam strong
market potenti oral administr vs spinraza everi
month intrathec inject potenti differenti efficaci could
larg supplant spinraza current market leadership expect
zolgensma captur vast major incid type sma
popul anticip risdiplam emerg domin therapi
older sma patient outlin introduct integr sma
dynam model expect risdiplam ultim expand total treat
sma popul estim adult sma patient
us spinraza expect segment grow oral agent
market roche/ptc plan file risdiplam nda/maa base
data later year estim drug could achiev
peak annual sale receiv tier royalti mid-teen
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
biotechnolog compani focus
develop manufactur small molecul therapeut
address multipl area includ rare disord oncolog
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base probabl
success risdiplam stabl translarna sale post
po aadc gene therapi
grey sky valuat assum valu risdiplam
 premium
 close
compani mention price
